anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Mitogen-activated protein kinase (MAPK)signaling-mediated smoking-associated pulmonary vascular remodeling (PVR) plays an important role in the pathogenesis of group 3 pulmonary hypertension (PH). And G protein pathway suppressor 2 (GPS2) could suppress G-protein signaling such as Ras and MAPK, but its role in cigarette smoking -induced PVR (CS-PVR) is unclear.
METHODS: An in vivo model of smoke-exposed rats was constructed to assess the role of GPS2 in smoking-induced PH and PVR. In vitro, the effects of GPS2 overexpression and silencing on the function of human pulmonary arterial smooth cells (HPASMCs) and the underlying mechanisms were explored.
RESULTS: GPS2 expression was downregulated in rat pulmonary arteries (PAs) and HPASMCs after CS exposure. More importantly, CS-exposed rats with GPS2 overexpression had lower right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RVHI), and wall thickness (WT%) than those without. And enhanced proliferation and migration of HPASMCs induced by cigarette smoking extract (CSE) can be evidently inhibited by overexpressed GPS2. Besides, GPS2siRNA significantly enhanced the proliferation, and migration of HPASMCs as well as activated Ras and Raf/ERK signaling, while these effects were inhibited by zoledronic acid (ZOL). In addition, GPS2 promoter methylation level in rat PAs and HPASMCs was increased after CS exposure, and 5-aza-2-deoxycytidine (5-aza) inhibited CSE-induced GPS2 hypermethylation and downregulation in vitro.
CONCLUSIONS: GPS2 overexpression could improve the CS-PVR, suggesting that GPS2 might serve as a novel therapeutic target for PH-COPD in the future.
The invention relates to a traditional Chinese medicine tea bag for preventing and treating myopia. The traditional Chinese medicine bag contains the following traditional Chinese medicines in parts by weight: 13 g of chrysanthemum, 10 g of wolfberry, 10 g of mulberry, 18 g of schisandra chinensis, 15 g of rhizoma cimicifugae, 16 g of caulis sinomenii, 7 g of angelica sinensis, 10 g of safflower, 12 g of cartialgenous, 9 g of buddleja officinalis, 10 g of puncturevine caltrop fruits, 23 g of caulis spatholobi and 12 g of borneol (synthesized camphol). The traditional Chinese medicine tea bag for preventing and treating myopia is sanitary in filling, free of pollution and environment-friendly. The prepared traditional Chinese medicine tea bag contains no impurities, and has a unique faint scent of the traditional Chinese medicines. After being brewed with hot water, the tea has a fresh and cool taste without any peculiar smell, and no suspension or sediment appears and no sugar or acid crystalizes when the tea is placed for a long time. The traditional Chinese medicine tea bag for preventing and treating myopia has an obvious curative effect and is convenient to use.
Intermittent hypoxia (IH) is an independent risk factor for metabolic dysfunction-associated fatty liver disease (MAFLD). Copper deficiency can disrupt redox homeostasis, iron, and lipid metabolism. Here, we investigated whether hepatic copper deficiency plays a role in IH-associated MAFLD and explored the underlying mechanism(s). Male C57BL/6 mice were fed a western-type diet with adequate copper (CuA) or marginally deficient copper (CuD) and were exposed separately to room air (RA) or IH. Hepatic histology, plasma biomarkers, copper-iron status, and oxidative stress were assessed. An in vitro HepG2 cell lipotoxicity model and proteomic analysis were used to elucidate the specific targets involved. We observed that there were no differences in hepatic phenotypes between CuA-fed and CuD-fed mice under RA. However, in IH exposure, CuD-fed mice showed more pronounced hepatic steatosis, liver injury, and oxidative stress than CuA-fed mice. IH induced copper accumulation in the brain and heart and exacerbated hepatic copper deficiency and secondary iron deposition. In vitro, CuD-treated cells with IH exposure showed elevated levels of lipid accumulation, oxidative stress, and ferroptosis susceptibility. Proteomic analysis identified 360 upregulated and 359 downregulated differentially expressed proteins between CuA and CuD groups under IH; these proteins were mainly enriched in citrate cycle, oxidative phosphorylation, fatty acid metabolism, the peroxisome proliferator-activated receptor (PPAR)α pathway, and ferroptosis. In IH exposure, CuD significantly upregulated the ferroptosis-promoting factor arachidonyl-CoA synthetase long chain family member (ACSL)4. ACSL4 knockdown markedly eliminated CuD-induced ferroptosis and lipid accumulation in IH exposure. In conculsion, IH can lead to reduced hepatic copper reserves and secondary iron deposition, thereby inducing ferroptosis and subsequent MAFLD progression. Insufficient dietary copper may worsen IH-associated MAFLD.
FIELD: equipment and method used in cosmetics. SUBSTANCE: aerosol apparatus has container with hair fixing composition including liquid phase comprising one fixing material in suitable solvent, and composition spraying device. Hair fixing material has vitrification temperature of at least 30 C. Hair fixing material has grafted organosilicon polymer with polysiloxane structure grafted with anionic hydrocarbon radical. Apparatus provides wetting capacity of at least 30 mg/s. Method involves treating keratin filaments by applying hair fixing composition to filaments by spraying device to provide for wetting capacity of at least 30 mg/s. Composition imparts softness, easy combing and other qualities to hair allowing good hair-do to be provided. EFFECT: simplified construction and method and provision for improved hair-style. 12 cl, 2 ex
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.

There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with amoxicillin, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, amoxicillin should be discontinued and appropriate therapy instituted.
Erythritol-based powder (PLUS®, EMS SA, Nyon, Switzerland) was used for air polishing the samples belonging to this group. All surfaces were numbered and application was made to the mesial and distal surfaces of the root, buccal and lingual surfaces of the crown to avoid repeated instrumentations. After device and samples were fixed, a metal plate with a 5 mm diameter hole was placed on the sample to limit the application area. Surfaces one and three were air-polished using the with a medium power setting (9 LED power setting), and surfaces two and four were air-polished using the with a maximum power setting (17 LED power setting). The distance between the handpiece and the tooth surface was kept constant at 5 mm, and the treatment angulation was adjusted to 60 degrees. In all applications, the application time was 5 seconds and the water setting was medium (6 LED). The powder chambers of the device were filled to the maximum level in each application.
PURPOSE:To obtain a carcinogenesis promoter-inhibiting agent containing bisbenzylisoquinoline type alkaloid as an active ingredient. CONSTITUTION:A promoter-inhibiting agent of carcinogenesis containing bisbenzylisoquinoline type alkaloid (e.g. cepharanthine, cepharanoline, homoaromoline, etc.) expressed by the formula (R1 and R2 are OH or methoxy; R3 is H: R4 and R5 are methoxy; R6 and R7 are H, OH or methoxy; dotted line is single bond or double bonds; R is H or methyl when R is single bond) as an active ingredient. The compound expressed by the formula may be directly used as the above-mentioned inhibiting agent, but usually used by adding an excipient, binder, lubricant, etc., to the compound expressed by the formula and formulating the compound to tablet, abstract, etc. The compound is usually administered in an amount of 10-1,000mg, preferably 30-300mg per day as an active ingredient when orally administered.
Participants will receive single oral dose of macitentan formulated as dispersible final market image (FMI) in fasted conditions (test) (Treatment A) in Intervention Period 1 followed by a single oral dose of film-coated opsumit tablet in fasted conditions (reference) (Treatment B) in Intervention Period 2 on Day 1. There will be washout period of at least 10 days between two period.
Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
A trading system is disclosed which allows an exchange to protect market data from electronic reproduction by traders but allows the traders to use the market data (such as the last traded price, current resting bids and offers) to assist in making the trades. The system includes an exchange server having a database having market data relating to commodities traded over the exchange. A group of trader computers each having a display are coupled to the exchange server. The trader computers have a trader interface run on the computer allowing each trader to place and accept orders for commodities traded over the exchange. The trader interface is capable of receiving market data from the exchange server. An external data source such as an Excel spreadsheet is stored on the trader computer having at least one data field. A  trader module is coupled to the trader interface and external data source. The trader module reads market data from the trader interface and the at least one data field of the external data source. The trader module displays the market data and the one data field on the display. The displayed data cannot be exported to the external data source but can be used to make trading decisions and manage orders.
### GLUCOVANCE

Patients should be informed of the potential risks and benefits of GLUCOVANCE and alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions; a regular exercise program; and regular testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters.

The risks of lactic acidosis associated with metformin therapy, its symptoms, and conditions that predispose to its development, as noted in the WARNINGS and PRECAUTIONS sections, should be explained to patients. Patients should be advised to discontinue GLUCOVANCE immediately and promptly notify their health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of GLUCOVANCE, gastrointestinal symptoms, which are common during initiation of metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal symptoms could be due to lactic acidosis or other serious disease.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members.

Patients should be counseled against excessive alcohol intake, either acute or chronic, while receiving GLUCOVANCE. (See Patient Information printed below.)
PROBLEM TO BE SOLVED: To obtain a multidrug resistance-overcoming agent and anticancer function promotor, free from calcium antagonistic activity, having a low cytotoxicity and capable of overcoming multidrug resistance of a cancer by compounding a specific solanesylethylenediamine derivative as an active component. SOLUTION: This agent contains a compound of formula I [(n) is 5-12; R1 and R2 are each a benzyl group (the phenyl ring of the benzyl group can be substituted with OH, an alkyl, an alkoxy, a halogen or methylenedioxy), but the case where R1 and R2 are each formula II at the same time is excluded] or a pharmaceutically permissible salt of the compound. As an example of a compound of formula I, N,N'-bis(3,4diethoxybenzyl)-N solanesylethylenediamine of formula III is cited. A compound of formula 1 is obtained e.g. by reacting a compound of formula IV with a compound of formula V (X is a leaving group such as a halogen). This drug composition is useful as an anticancer function promoter on an anticancer agent for brain tumor, kidney cancer, adrenal cancer, large intestinal cancer, small intestinal cancer, colon cancer, lung cancer, liver cancer, etc.  As an anticancer agent, taxol or its derivative is suitable.
Immune checkpoint inhibitors (ICIs) have emerged as an integral component of the management of various cancers and have contributed to significant improvements in overall survival. Most available ICIs target anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4), and anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD1/PDL1). Gastrointestinal immune-related adverse events remain a common complication of ICIs. The predominant manifestations include diarrhea and colitis, which often manifest concurrently as immune-mediated diarrhea and colitis (IMDC). Risk factors for developing these side effects include baseline gut microbiota, preexisting autoimmune disorders, such as inflammatory bowel disease, and type of neoplasm. The hallmark symptom of colitis is diarrhea which may be accompanied by mucus or blood in stools. Patients may also experience abdominal pain, fever, vomiting, and nausea. If not treated rapidly, ICI-induced colitis can lead to serious life-threatening complications. Current management is based on corticosteroids as first-line, and immunosuppressants like infliximab or vedolizumab for refractory cases. Microbiota transplantation and specific cytokines and lymphocyte replication inhibitors are being investigated. Optimal patient care requires maintaining a balance between treatment toxicity and efficacy, hence the aim of this review is to enhance readers' comprehension of the gastrointestinal adverse events associated with ICIs, particularly IMDC. In addition to identifying the risk factors, we discuss the incidence, clinical presentation, workup, and management options of IMDC.
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Y 12  receptor antagonist compound, wherein said amount is effective to bind the P2Y 12  receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y 12  receptor antagonist compounds useful for this invention include mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5′-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.
The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
In patients with 18q deletion syndrome (18q-), immunodeficiency, autoimmunity, and allergies have been described in a subset. Pitt-Hopkins syndrome represents a specific subset of patients with 18q- who have a proximal deletion involving the TCF4 gene or a TCF4 variant. Immunodeficiency has been reported in the overall 18q- population; however, immunodeficiency with Pitt-Hopkins syndrome has not been highlighted. This case report details the immunologic evaluations and the associated infections seen in a young adult with Pitt-Hopkins syndrome to underscore the challenges of managing adults with a complex phenotype who develop frequent infections. This patient with Pitt-Hopkins syndrome ultimately fulfilled the diagnostic criteria for common variable immunodeficiency. Immunoglobulin replacement has led to a somewhat improved infection pattern, although she continues to have aspiration events leading to pneumonia. This case highlights the clinical evolution of Pitt-Hopkins syndrome and serves as a reminder that immunodeficiency can occur in this syndrome.
FIELD: immunology. SUBSTANCE: Anant-II is the conjugated antigen to kidney antibody. It does not contain serum albumin, does not cause allergic reactions and does not decrease organism resistance. Agent is used for prevention of the transplanted kidney detachment. Anant-II is used as injections at concentration 3% in saline solution at dose 0.1 ml per 1 kg weight, in 3 days up to 7 injections before kidney transplanting onset. EFFECT: enhanced effectiveness of agent.
Microparticles (MPs) are small membrane bound vesicles shed from the surface of a variety of cells by what appear to be well regulated processes. They are elevated in many physiological and disease states and in some instances have been associated with organ injury. Shear stress - as can be caused by intravascular bubbles - is one of the stimuli known to cause cells to release microparticles. Most sport SCUBA dives have been shown to generate intravascular bubbles - even safe dives well within limits established by the US Navy and sports authorities. The investigators have reported elevations in several sub-types of MPs in a group of individuals undergoing a well monitored series of open-water SCUBA dives. There is no information of the occurrence of MPs in injured divers. The investigators have published results using a murine model which demonstrated that mice subjected to varying decompression stresses exhibit progressive elevations in circulating MPs derived from leukocytes, erythrocytes, platelets and endothelial cells. Using novel interventions the investigators demonstrated that MPs cause intravascular neutrophil activation and inflammatory perivascular injuries. Therefore, there is pathophysiological information to suggest that one or more element of MPs (number and/or pro-inflammatory subtype) may be proximal elements that precipitate the clinical syndrome the investigators call decompression sickness.
The invention relates to a prescription matching system and a matching method, comprising a servo end, a first communication unit and a second communication unit. The patient transmits a prescription image data to the server through the first communication unit, and the server recognizes the prescription image data through an identification module to generate a prescription text data and transmits the prescription text data to the second communication unit. The drug bureau compares the text information of the prescription with an inventory information through the second communication unit and returns a confirmation message to the server. After receiving the confirmation message, the server transmits a medicine-receiving data to the first communication unit. After receiving the medicine receiving data, the patient can get medicine from the medicine bureau corresponding to the second communication unit. The matching system and the matching method can facilitate the patient to replace the drug bureau for taking the drug so as to improve the convenience of taking the drug.
Disclosed are novel non-reducing saccharide-forming enzyme, and its preparation and uses. The enzyme is obtainable from the culture of microorganisms such as Rhizobium sp. M-11 (FERM BP 4130) and Arthrobacter sp. Q36 (FERM BP-4316), and capable of forming non-reducing saccharides having a trehalose structure when allowed to act on reducing partial starch hydrolysates. Glucoamylase and α-glucosidase readily yield trehalose when allowed to act on the non-reducing saccharides. These non-reducing saccharides and trehalose are extensively useful in food products, cosmetics and pharmaceuticals.
The present invention relates to a machine enabling the automatic sorting of defective gelatin capsules on the basis of the diameter thereof and the weight thereof. Said device can be used on machines producing partially closed, empty gelatin capsules and at the inlet and the outlet of machines filling said gelatin capsules. Said machine enables the automatic selection and rejection of the gelatin capsules having assembly and metering defects. The device consists of a rimmed selection disk rotating on an inclined plane of about 20 degrees relative to the horizontal direction. Said disk has one or two rows of sized apertures drilled on the circumference thereof and holding said misassembled gelatin capsules until the automatic expulsion thereof through a blast nozzle. The gelatin capsules without assembly defects freely pass through the sized apertures. During the fall thereof, the gelatin capsules individually pass in front of a blast screen selecting the empty or poorly metered gelatin capsules. The gelatin capsules meeting the standards are not diverted by the air blast and are discharged from the machine via the outlet chute.
To provide treatment of ovarian cancer with anti-CD47 and anti-PD-L1.SOLUTION: The present description provides a method for treating an individual with ovarian cancer using an anti-CD47 antibody and an anti-PD-L1 antibody. The method of the present invention involves the administration of anti-CD47. In some embodiments, the antibody comprises a human IgG4 Fc region. In some embodiments, the anti-CD47 antibody competes with Hu5F9-G4 for binding to CD47. In some embodiments, the anti-CD47 binds to the same CD47 epitope as Hu5F9-G4. In other embodiments, the anti-CD47 antibody is Hu5F9-G4.SELECTED DRAWING: None
Large sessile and laterally spreading colorectal lesions(LSLs) are increasingly encountered during colonoscopy. LSLs have an increased risk of harbouring invasive cancer and can be challenging to excise endoscopically. Wide-field endoscopic mucosal resection (WF-EMR) is widely used in treating LSLs. In the East, meanwhile endoscopic submucosal dissection (ESD) is the dominant technique due to its ability to achieve en bloc resection in over 80% of cases. Many papers have demonstrated that selective-esd has the highest economic benefit. The key is to find a reliable way to select.